SEC Form 4 · accession 0001179110-17-004065
Tempest Therapeutics, Inc. · TPST
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Christophe Couturier
Officer — Chief Financial Officer
Period of report
Mar 2, 2017
Accepted (ET)
Mar 6, 2017 · 8:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001544227
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.49 | Mar 2, 2017 | A | 45,750 | A | — | Mar 2, 2027 | Common Stock | 45,750 | 45,750 | D |
Explanation of responses
- F1The option vests as to 25% of the option shares on March 2, 2018 and vests as to an additional 6.25% of the option shares at the end of each successive three-month period thereafter until March 2, 2021.